Vaccine Adjuvants Market Overview
The vaccine adjuvants market was valued at approximately USD 665.86 million in 2020, and it is expected to witness a revenue of USD 1478.32 million in 2026, with a CAGR of 13.37% over the forecast period, 2021-2026. The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing the use of recombinant subunit and synthetic vaccines.
Download free sample here – Vaccine Adjuvants Market
Impact of COVID-19 in Vaccine Adjuvants Market
According to a research article in Nature Reviews Immunology 2020, aluminum-based vaccine adjuvants offer a glide path to induce high levels of neutralizing antibody, which is increasingly recognized as a cornerstone of the protection afforded by COVID-19 vaccines. Additionally, in May 2020, GSK intended to produce 1 billion doses of its pandemic vaccine adjuvant system in 2021 to support the development of multiple adjuvanted COVID-19 vaccine candidates. Thus, the COVID-19 pandemic is expected to significantly impact the studied market growth positively.
Vaccine Adjuvants Market – Geographical Overview
North America holds a significant share in the vaccine adjuvants market during the forecast period
The major factors driving the vaccine adjuvants market’s growth in the North American region are the presence of key market players, the availability of advanced technologies, and the increasing expenditure on R&D for vaccines. According to the Centers for Disease Control and Prevention (CDC), adjuvants such as aluminum hydroxyphosphate sulfate, monophosphoryl lipid A (MPL) + aluminum salt, oil-in-water emulsions composed of squalene, MPL, and QS-21 (a natural compound from Chilean soapbark tree combined in a liposomal formulation), and cytosine phosphoguanine (CpG) are currently used in vaccines such as DtaP (Daptacel, Infanrix), Hep A (Havrix, Vaqta), Hep B (Engerix-B, Recombivax), HPV (Gardasil 9), Pneumococcal (Prevnar 13), Cervarix, Fluad, Shingrix, and Heplisav-B in the United States. Furthermore, there has been a growing interest in adjuvant technology for the development of vaccines against COVID-19, and this scenario is expected to drive the studied market growth in the region during the pandemic.
Check our other latest reports on –
Key Highlights of the Vaccine Adjuvants Market
Related Reports and Links
List of Key Players in the Vaccine Adjuvants Market
*List Not Exhaustive
Mordor Intelligence has segmented the global vaccine adjuvants market on the basis of type, usage, disease type, application, and geography:
About Mordor Intelligence
Mordor Intelligence is a market intelligence and advisory firm. Our mission is to map complex business ecosystems across the globe to better predict butterfly effects. To date, we have partnered with 4000+ enterprises across 20 industries, to deliver precise data and actionable insights in over 6000 projects. Our domain-specific teams of research experts continuously track markets, enabling our clients to gain a competitive edge through high-quality market intelligence.
We offer fully tailored intelligence solutions to meet the unique business requirements of any organization. Our deep industry expertise coupled with cross-functional analyst teams ensures we can support the intelligence requirements of even the most specific of business problems.
Media ContactCompany Name: Mordor Intelligence Private LimitedContact Person: Bhargav PEmail: Send EmailPhone: +1 617-765-2493Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli City: HyderabadState: Telangana 500008Country: IndiaWebsite: https://www.mordorintelligence.com/industry-reports/vaccine-adjuvants-market?utm_source=press-release&utm_medium=Outbound&utm_campaign=51331&utm_id=AB_Newswire&utm_content=PR1